Prostate Artery Embolization vs. UroLift: Which BPH Treatment Is Right for You?

Key Takeaways

• PAE and UroLift use different mechanisms to reduce urinary obstruction from BPH.
• UroLift places permanent implants through the urethra to retract obstructing prostate tissue.
• PAE is performed through an artery and reduces blood flow to selected prostate tissue, leading to gradual tissue shrinkage.
• Current U.S. UroLift labeling includes lateral and median lobe hyperplasia in men aged 45 or older with prostates up to 100 cc.
• PAE does not have the same device-based 100 cc upper-volume limit, but vascular anatomy and other clinical factors can affect candidacy.
• Both treatments are commonly considered when preservation of sexual function is important, but neither procedure can guarantee unchanged erectile or ejaculatory function.
• There is no direct randomized head-to-head trial proving that PAE or UroLift is superior for all patients.
• Evaluation of urinary symptoms, prostate anatomy, bladder function, and treatment goals is essential before choosing either procedure.
• Choosing between PAE, UroLift, or another BPH treatment starts with confirming what is causing the urinary symptoms. North Star combines urologic evaluation with PAE expertise so patients can better understand which treatment options fit their prostate anatomy, urinary function, medical history, and goals.

Prostate artery embolization (PAE) and UroLift, also called prostatic urethral lift (PUL), can both be used to treat bothersome lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH). They are not interchangeable procedures, however. UroLift mechanically opens the prostatic urethra with permanent implants, while PAE reduces blood flow to selected prostate tissue so the gland can shrink over time.
Neither treatment is automatically better for every patient. The more important question is which treatment, if either, fits the cause of the urinary symptoms, prostate size and anatomy, bladder function, symptom severity, previous treatment, medical history, and the patient’s priorities. Current evidence supports shared decision-making rather than choosing a procedure from prostate size or symptom score alone.

At North Star Prostate Center, patients can approach that decision through multidisciplinary prostate care rather than beginning with the assumption that a specific procedure is the answer. North Star offers urology care alongside prostate artery embolization, bringing urologic evaluation and minimally invasive PAE expertise into the same setting. For someone comparing PAE vs. UroLift, that broader evaluation can help clarify whether PAE, a urologic treatment, or another management approach should be considered.

A systematic review and network meta-analysis found broadly similar outcomes for PAE and PUL, but the comparison was indirect and the authors rated the available evidence as relatively limited.

PAE vs UroLift

How Does UroLift Work?

UroLift treats obstruction by changing the position of prostate tissue rather than removing it. A urologist passes a delivery device through the urethra and places small implants that pull selected prostate tissue away from the urethral channel. The implants remain in place to keep the channel more open.
According to current U.S. UroLift patient safety information, the system is indicated for urinary outflow obstruction from BPH, including lateral and median lobe hyperplasia, in men age 45 and older. It should not be used when prostate volume is greater than 100 cc and has other contraindications, including active urinary tract infection, current gross hematuria, urinary incontinence from an incompetent sphincter, and urethral conditions that prevent device insertion.
Because the procedure does not cut, heat, or remove prostate tissue, UroLift is often discussed with patients who want a minimally invasive option and who place a high value on preserving ejaculation. Candidacy still depends on the individual anatomy and the clinician’s assessment.

How Does PAE Work?

PAE approaches the prostate through its arterial blood supply. An interventional radiologist advances a small catheter through an artery, maps the vessels supplying the prostate, and delivers embolic particles into selected prostatic arteries. The resulting reduction in blood flow causes ischemic change in targeted prostate tissue, followed by gradual reduction in prostate volume.
PAE is technically demanding because pelvic arterial anatomy varies from patient to patient and branches supplying the prostate can communicate with nearby organs. Careful angiographic mapping is used to reduce the risk of non-target embolization. The Society of Interventional Radiology published updated PAE practice guidance in June 2026.
At North Star, PAE is described as an outpatient treatment performed through a small arterial access site, generally without general anesthesia. Exact sedation, access route, medications, and post-procedure instructions are individualized.

Is PAE More Effective Than UroLift?

Current evidence does not justify saying that PAE is universally more effective than UroLift. Importantly, there is no randomized trial directly assigning patients to PAE versus UroLift.
The best-known comparison is an indirect network meta-analysis of randomized trials that used TURP or sham treatment as common comparators. It found similar overall clinical efficacy and safety profiles for PAE and PUL, while also emphasizing that the evidence was limited and should be interpreted cautiously. See the BJU International review on PubMed.
For an individual patient, a procedure may look more or less favorable depending on the treatment goal. Objective urinary flow, symptom relief, catheter dependence, desire to avoid permanent implants, prostate size, vascular anatomy, and preservation of sexual function can all carry different weight.

Does Prostate Size Matter for PAE or UroLift?

Yes, but prostate size is only one part of treatment selection.
Current U.S. UroLift labeling states that the system should not be used when prostate volume is greater than 100 cc. The label includes treatment of lateral and median lobe hyperplasia. That is important because older articles and older guideline summaries may still describe narrower selection criteria.
PAE is not governed by a fixed device-volume indication in the same way. It has been studied in populations with substantially larger prostates. For example, a 2025 single-center cohort of 1,075 PAE patients had a median prostate volume of 107 g. That study showed sustained symptom improvement in follow-up, but it was observational and should not be interpreted as proof that every large prostate is an appropriate PAE candidate. Review the study on PubMed.
Prostate shape, intravesical protrusion, bladder function, arterial anatomy, prior prostate procedures, and the reason for the urinary symptoms can be as important as prostate volume.

Which Treatment Is Better for Preserving Sexual Function?

Both treatments are often considered when sexual side effects are a major concern, but the most accurate wording is that they have favorable sexual-function profiles in published studies, not that either procedure guarantees preservation.
For UroLift, the current manufacturer safety page states that the pivotal study reported no new sustained erectile or ejaculatory dysfunction. Long-term follow-up of the L.I.F.T. study also reported preservation of sexual function through five years. Read the five-year UroLift study on PubMed.
For PAE, randomized and systematic-review evidence generally shows little change in erectile function compared with baseline or TURP, and some evidence suggests fewer ejaculatory disorders than TURP. However, the certainty of evidence for several sexual-function outcomes is low, and ejaculatory changes can occur. See the Cochrane review on PubMed.
Baseline erectile function, medications, age, diabetes, vascular disease, and other conditions can affect sexual outcomes regardless of which BPH procedure is selected.

How Does Recovery Compare?

Recovery After UroLift

UroLift is commonly performed as an outpatient procedure. According to current Teleflex patient information, most patients do not typically require a catheter. When a catheter is needed, the average duration reported by the manufacturer is about one day. Return to normal activity is often within a few days, although recovery varies.
Temporary side effects can include painful or uncomfortable urination, urgency, urge incontinence, pelvic pain, and blood in the urine. Bleeding and infection are less common but can be serious. Review current UroLift safety information.

Recovery After PAE

PAE is also commonly performed on an outpatient basis. Patients may experience post-embolization symptoms such as burning with urination, pelvic or local pain, urinary frequency, fatigue, or other temporary irritative urinary symptoms. A systematic review found dysuria or urethral burning and local pain among the most commonly reported components of post-embolization syndrome. Read the systematic review on PubMed.
Temporary catheterization is not required for every PAE patient, but acute urinary retention is a recognized adverse event and catheter needs depend on baseline retention, bladder function, prostate swelling, and the clinical course. Patients who already use a catheter require individualized planning.

What Are the Risks of PAE and UroLift?

Every BPH procedure has potential complications. A balanced comparison should include these risks rather than focusing only on recovery time.

Potential PAE Risks

• Post-embolization symptoms such as pelvic pain, dysuria, urinary frequency, or fatigue.
• Urinary tract infection or acute urinary retention.
• Blood in the urine or semen.
• Bleeding, bruising, or vascular complications at the arterial access site.
• Rare non-target embolization affecting nearby pelvic structures.
• Need for repeat BPH treatment if symptoms recur or remain bothersome.

Potential UroLift Risks

• Dysuria or discomfort with urination.
• Urinary urgency or urge incontinence.
• Pelvic pain.
• Blood in the urine.
• Temporary urinary retention or catheter use in some patients.
• Bleeding or infection, which can rarely be serious.
• Need for additional BPH treatment if symptoms persist or recur.

How Durable Are PAE and UroLift?

Both procedures can provide durable symptom improvement, but retreatment remains possible and study designs differ.
The five-year L.I.F.T. study of UroLift reported a 13.6% surgical retreatment rate. That figure applies to the population and protocol studied and should not be presented as a guaranteed individual outcome.
A 2025 observational study of 1,075 PAE patients reported that 16% of reintervention-eligible patients underwent a second prostatic intervention by up to 60 months. The study also reported sustained symptom improvement among patients with longer follow-up. Because this was not a randomized comparison with UroLift and the populations differed, the percentages should not be used to claim that one treatment is more durable than the other.

Who May Be Considered for UroLift?

UroLift may be discussed when urinary symptoms are attributed to BPH and prostate anatomy fits the device indication and treatment plan. Considerations may include:

• Bothersome urinary symptoms linked to BPH.
• A prostate volume within current U.S. device labeling.
• Anatomy that the treating urologist believes can be effectively treated with PUL.
• A preference to avoid tissue resection or thermal ablation.
• A strong preference to preserve erectile and ejaculatory function.
• Acceptance of permanent implants in the prostate.

Current labeling also lists contraindications that must be reviewed before treatment. A urologist determines whether the procedure is appropriate.

Who May Be Considered for PAE?

PAE may be discussed when a patient has bothersome LUTS attributed to BPH and wants to consider an arterial, non-resection treatment. Potential reasons to evaluate PAE include:

• Persistent moderate to severe urinary symptoms despite conservative care or medication.
• Medication side effects or a desire to discuss a procedural alternative.
• A preference to avoid transurethral tissue treatment.
• A large prostate or anatomy for which additional treatment options should be considered.
• A desire to avoid a permanent mechanical prostate implant.
• Concern about sexual side effects from other BPH treatments.
• Medical factors that make treatment planning more complex and warrant multidisciplinary review.

PAE is not appropriate for every patient. Arterial anatomy, kidney function, contrast considerations, infection, prostate cancer evaluation when indicated, bladder function, and the true cause of urinary symptoms may affect candidacy.

What Testing Is Needed Before Choosing a BPH Procedure?

Lower urinary tract symptoms are not specific to BPH. Weak stream, urgency, frequency, incomplete emptying, and nocturia can also result from bladder dysfunction, urethral disease, infection, neurologic conditions, medication effects, or other causes.
Depending on the patient, evaluation may include:

• Medical and urinary symptom history.
• International Prostate Symptom Score (IPSS).
• Medication and prior-procedure review.
• Urinalysis and other laboratory testing when indicated.
• PSA testing and prostate cancer evaluation when appropriate.
• Prostate volume and anatomy assessment.
• Urinary flow measurement.
• Post-void residual measurement.
• Bladder function assessment or urodynamic testing in selected cases.
• Imaging needed for treatment planning.

At North Star, this evaluation is an important part of treatment planning rather than simply a step toward PAE. The center offers in-house urology care alongside its PAE program, allowing urinary symptoms, prostate anatomy, bladder function, and other possible causes of lower urinary tract symptoms to be assessed before a procedural option is selected. This multidisciplinary approach can be especially useful for patients who are still deciding among PAE, UroLift, medication, or other BPH treatment approaches.

PAE Evaluation in Golden Valley and Minneapolis, Minnesota

North Star Prostate Center is located at 8401 Golden Valley Road, Suite 340, Golden Valley, Minnesota, and serves patients from Minneapolis, St. Paul, and surrounding Twin Cities communities.
North Star Prostate Center focuses on helping men understand the cause of their urinary symptoms and the treatment options that may be appropriate for them. Its multidisciplinary urology and PAE capabilities allow patients comparing PAE vs. UroLift to review prostate size and anatomy, bladder function, previous treatment, medical history, recovery preferences, and personal priorities before deciding on the next step. The goal of the consultation is to determine treatment fit rather than assume that a particular procedure is right for every patient.
Review North Star’s BPH information or contact the center to request an evaluation.

Medical disclaimer: This article is for general educational purposes and is not a substitute for individual medical advice. BPH treatment depends on the cause and severity of urinary symptoms, prostate size and anatomy, bladder function, medical history, medications, prior procedures, and personal goals. A qualified clinician should determine which options are appropriate for an individual patient.